Fluoguide with positive phase II results: Danish Biotech Weekly (36)

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, Fluoguide reported positive phase 2 data while Expres2ion presented poor phase 3 data. 2Curex launched two products and Zealand Pharma announced designation of priority review by the US FDA. Finally, two companies reported earnings and one more will follow this week.

The past week was full of interesting news with 11 of the 20 listed Danish biotech companies publishing news. 10 of the 20 companies had a positive share price development the past week and 9 companies have a positive share price performance year to date. Saniona overtook Fluoguide as the best performing stock year-to-date. SynAct Pharma was until today the best performing stock the 12 months.

Company news the past week

Ascendis Pharma

Ascendis Pharma is set to report earnings on September 5 (Link). Analysts expects 37.35 MEUR in revenue and a loss of EUR 2.59 per share.

Biosergen

Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million (Link)

Cessatech

No news the past week

CS Medica

CS MEDICA A/S Achieves Milestone with Patent on Nasal Night Spray (Link)

Curasight

No news the past week

Evaxion Biotech

Evaxion announces Executive Management Changes to strengthen the AI-strategy (Link)

Expres2ion

ExpreS2ion Biotechnologies: Phase III secondary endpoint data announced for the COVID-19 booster vaccine candidate (Link)

Fluoguide

FluoGuide A/S issues warrants to the investors participating in the directed share issue (Link)

FluoGuide completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer (Link)

FluoGuide reports further positive interim data from phase IIa trial of FG001 in head & neck cancer (Link)

FluoGuide A/S publishes interim report for the period January – June 2023 (Link)

Genmab

Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference (Link)

Gubra

Gubra resumes its share buy-back programme to hedge incentive scheme obligations (Link)

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

Saniona publishes its interim report for the second quarter of 2023 (Link)

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week, but has today annonced that the phase 2B triels did not meet the primary endpoint (Link)

ViroGates

No news the past week

Zealand Pharma

Sale of shares in Zealand Pharma A/S by a board member (Link)

Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism (Link)

Y-mAbs Therapeutics

No news the past week

2cureX

2cureX launches its first two IndiTreat® products CE-marked under the new IVD Regulation (Link)

SELECTED CASES

SHARE PRICE DEVELOPMENTS

On average, the Danish biotech stocks delivered a positive share price performance last week of 0.2%. Notably, the three best performing companies did not report any news during the week. Fluoguide completed patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer and presented positive interim data from phase IIa trial of FG001 in head & neck cancer. The worst performer of the week became Expres2ion after presenting Phase III secondary endpoint data for the COVID-19 booster vaccine candidate. The reason behind the falling share price was that Expression Biotech’s partner Bavarian Nordic saw a lower level of neutralizing antibodies for its COVID-19 vaccine candidate in the completed Phase 3 study than for the vaccines it was compared to in the study. The best stocks year-to-date include Curasight, Fluoguide, and Saniona after soaring 121-155%. Overall, the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 6.4%. However, it is driven by the few companies delivering very positive returns.

Read more about Curasight (in Danish): Et succesfuldt kvartal for Curasight med mere i vente

Overview of share price developments the past week, year-to-date and last twelve months

Disclaimer 

Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email